Literature DB >> 7095844

Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.

B R Murphy, D L Nelson, P F Wright, E L Tierney, M A Phelan, R M Chanock.   

Abstract

An enzyme-linked immunosorbent assay was used to measure isotype-specific antibody to purified hemagglutinin (HA) of influenza A virus, using serum and nasal-wash specimens from young children undergoing primary infection with live cold-adapted influenza A/Alaska/77 (H3N2) or A/Hong Kong/77 (H1N1) candidate vaccine virus. The serum antibody response followed the pattern expected for a primary viral infection. Each of 17 vaccinated children had a serum immunoglobulin G (IgG) HA antibody response, 16 had an IgM antibody response, and 13 had an IgA antibody response. Nasal-wash HA antibody was detected in the IgA, IgM, and IgG isotypes. Of the 17 vaccinated children, 14 had an IgA response, 13 had an IgM response, and 9 had an IgG response. Most of the IgA and IgM HA antibody was actively secreted locally, whereas only some of the IgG HA antibody could be shown to be actively secreted into the respiratory tract. There was a good correlation between the level of nasal-wash antibodies measured by the HA-specific IgA enzyme-linked immunosorbent assay and by a plaque neutralization assay. These data indicate that intranasal vaccination of susceptible children with live, attenuated, cold-adapted influenza A viruses efficiently stimulates both systemic and local antibody responses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7095844      PMCID: PMC551444          DOI: 10.1128/iai.36.3.1102-1108.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness.

Authors:  J C Perkins; D N Tucker; H L Knopf; R P Wenzel; A Z Kapikian; R M Chanock
Journal:  Am J Epidemiol       Date:  1969-12       Impact factor: 4.897

2.  Changes in IgA and IgG concentrations in nasal secretions prior to the appearance of antibody during viral respiratory infection in man.

Authors:  W T Butler; T A Waldmann; R D Rossen; R G Douglas; R B Couch
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

3.  Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus.

Authors:  P L Ogra; D Kerr-Grant; G Umana; J Dzierba; D Weintraub
Journal:  N Engl J Med       Date:  1971-12-09       Impact factor: 91.245

4.  Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2.

Authors:  L P Tremonti; J S Lin; G G Jackson
Journal:  J Immunol       Date:  1968-09       Impact factor: 5.422

5.  Protective effect of antibody to parainfluenza type 1 virus.

Authors:  C B Smith; R H Purcell; J A Bellanti; R M Chanock
Journal:  N Engl J Med       Date:  1966-11-24       Impact factor: 91.245

6.  Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. specific protective effect against epidemic disease.

Authors:  W P Edmondson; R H Purcell; B F Gundelfinger; J W Love; W Ludwig; R M Chanock
Journal:  JAMA       Date:  1966-02-07       Impact factor: 56.272

7.  Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.

Authors:  J Mills; J E Van Kirk; P F Wright; R M Chanock
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

8.  Respiratory syncytial virus neutralizing activity in nasal secretions following natural infection.

Authors:  H W Kim; J A Bellanti; J O Arrobio; J Mills; C D Brandt; R M Chanock; R H Parrott
Journal:  Proc Soc Exp Biol Med       Date:  1969-06

9.  Antibody response in respiratory secretions of volunteers given live and dead influenza virus.

Authors:  J J Mann; R H Waldman; Y Togo; G G Heiner; A T Dawkins; J A Kasel
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

10.  Identification in a recombinant influenza virus of structural proteins derived from both parents.

Authors:  W G Laver; E D Kilbourne
Journal:  Virology       Date:  1966-11       Impact factor: 3.616

View more
  59 in total

1.  In Memoriam: Robert M. Chanock, MD, 1924–2010.

Authors:  Albert Z Kapikian; David M Morens; Anthony S Fauci
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Detrimental Influence of Alveolar Macrophages on Protective Humoral Immunity during Francisella tularensis SchuS4 Pulmonary Infection.

Authors:  Donald J Steiner; Yoichi Furuya; Dennis W Metzger
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

3.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

4.  Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs.

Authors:  Valeria Alcon; Maria Baca-Estrada; Marco Vega-Lopez; Philip Willson; Lorne A Babiuk; Praveen Kumar; Rolf Hecker; Marianna Foldvari
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

5.  Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Authors:  M L Clements; R B Belshe; J King; F Newman; T U Westblom; E L Tierney; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

6.  Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus.

Authors:  M H Snyder; M L Clements; D De Borde; H F Maassab; B R Murphy
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

7.  Comparison by studies in squirrel monkeys, chimpanzees, and adult humans of avian-human influenza A virus reassortants derived from different avian influenza virus donors.

Authors:  M H Snyder; M L Clements; D Herrington; W T London; E L Tierney; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

8.  Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases.

Authors:  G J Gorse; R B Belshe; N J Munn
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

9.  Serological evaluation of an influenza A virus cold-adapted reassortant live vaccine, CR-37 (H1N1), in Japanese adult volunteers.

Authors:  N Yamane; Y Nakamura; M Yuki; T Odagiri; N Ishida
Journal:  J Hyg (Lond)       Date:  1984-04

10.  Molecular and biological changes in the cold-adapted "master strain" A/AA/6/60 (H2N2) influenza virus.

Authors:  M L Herlocher; H F Maassab; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.